Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid
lineage (red blood cells, platelets, and white blood cells other than B and T cells). Like other …

Large series of patients with acute myelogenous leukemia (AML) after ex vivo T cell-
depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) have not …

Molecular data and minimal residual disease (MRD) have been shown to influence
outcomes in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic …

We assessed the susceptibility of secondary acute myeloid leukaemia (sAML) to graft‐
versus‐leukaemia effects. Data from 2414 sAML patients in first (n= 2194) or second (n …

We provide a long‐term evaluation of patients enrolled in the EORTC/GIMEMA AML‐10 trial
which included a total of 2157 patients, 15‐60 years old, randomized to receive either …

The use of myeloablative conditioning (MAC) in umbilical cord blood transplantation (UCBT)
has been associated with high nonrelapse mortality (NRM) in patients aged> 40 years …

There have been several efforts to predict mortality after autologous stem cell transplantation
(ASCT), such as the hematopoietic cell transplant-comorbidity index (HCT-CI), described for …

We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial
which included a total of 2157 patients, 15-60 years old, randomized to receive either …

Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative treatment for acute
myeloid leukaemia (AML) in which donor-derived anti-leukaemia reactive T cells have an …